To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Locally Advanced or Metastatic HER2-Expressing Cancers
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 645 (planned)
- Started
- Apr 13, 2022
- Main results expected
- Apr 2028
- Fully finished
- Apr 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of dose-limiting toxicity - Part 1 and Part 2
Measured over: Up to approximately 21 days (Part 1) and 42 days (Part 2)
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)- Parts 1, 2, 3, and 4
Measured over: Up to approximately 55 months
Objective Response Rate (ORR) - Part 3 and Part 4
Measured over: Up to approximately 55 months
Duration of Response (DOR) - Part 3 and Part 4
Measured over: Up to approximately 55 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05356741 · record last updated 2026-08-19 · checked 2026-11-09 15:47 UTC